NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-19.41 Insider Own0.20% Shs Outstand78.14M Perf Week-30.94%
Market Cap1.76B Forward P/E8.15 EPS next Y2.58 Insider Trans-6.96% Shs Float77.85M Perf Month-43.35%
Income-1475.80M PEG- EPS next Q1.58 Inst Own44.50% Short Float20.06% Perf Quarter-59.36%
Sales1.29B P/S1.36 EPS this Y-222.50% Inst Trans1.80% Short Ratio2.55 Perf Half Y-73.81%
Book/sh-5.34 P/B- EPS next Y753.50% ROA-55.70% Target Price105.83 Perf Year-90.95%
Cash/sh- P/C- EPS next 5Y0.00% ROE- 52W Range20.46 - 257.30 Perf YTD-85.32%
Dividend- P/FCF- EPS past 5Y-2.50% ROI- 52W High-92.40% Beta1.76
Dividend %- Quick Ratio0.90 Sales past 5Y136.90% Gross Margin77.80% 52W Low-4.40% ATR2.46
Employees1541 Current Ratio1.00 Sales Q/Q-37.60% Oper. Margin- RSI (14)22.88 Volatility9.61% 7.76%
OptionableYes Debt/Eq- EPS Q/Q-37.40% Profit Margin- Rel Volume0.81 Prev Close21.00
ShortableYes LT Debt/Eq- EarningsAug 08 AMC Payout- Avg Volume6.13M Price19.56
Recom2.50 SMA20-35.63% SMA50-53.10% SMA200-73.06% Volume3,604,013 Change-6.86%
Sep-22-22Downgrade JP Morgan Neutral → Underweight $132 → $27
May-20-22Initiated BofA Securities Underperform $35
Feb-23-22Reiterated B. Riley Securities Buy $315 → $265
Feb-22-22Resumed Jefferies Buy $198
Jan-21-22Initiated Cowen Outperform $150
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Sep-26-22 06:00AM
Sep-25-22 06:07AM
Sep-24-22 08:14AM
Sep-23-22 06:13PM
10:51AM
Sep-22-22 04:43PM
04:11PM
02:00PM
01:17PM
11:15AM
10:53AM
10:26AM
10:06AM
08:11AM
03:49AM
Sep-20-22 09:00AM
Sep-19-22 06:18PM
11:31AM
Sep-18-22 10:28AM
Sep-17-22 05:00AM
Sep-16-22 08:18AM
08:15AM
08:10AM
Sep-15-22 05:50PM
12:25PM
Sep-14-22 04:35PM
Sep-13-22 11:20AM
08:00AM
Sep-12-22 11:16AM
10:25AM
09:23AM
07:37AM
Sep-08-22 01:00PM
10:45AM
Sep-07-22 04:02PM
11:30AM
09:00AM
Sep-06-22 12:35PM
Sep-05-22 01:08PM
Sep-02-22 01:56PM
01:45PM
Sep-01-22 01:37PM
11:02AM
Aug-31-22 06:45PM
02:54PM
05:21AM
Aug-30-22 06:00AM
Aug-29-22 08:54AM
Aug-27-22 06:08AM
Aug-26-22 03:22PM
12:46PM
09:27AM
Aug-24-22 04:31PM
Aug-23-22 09:25AM
Aug-22-22 05:29PM
04:16PM
12:33PM
11:42AM
10:43AM
09:30AM
08:04AM
07:36AM
Aug-21-22 10:05PM
08:45AM
Aug-19-22 07:14PM
06:23PM
04:13PM
11:00AM
Aug-18-22 12:18PM
08:54AM
08:00AM
Aug-17-22 12:18PM
08:00AM
Aug-16-22 12:32PM
Aug-15-22 06:45PM
11:08AM
10:04AM
09:28AM
08:39AM
08:19AM
08:14AM
08:00AM
Aug-14-22 09:53AM
Aug-12-22 10:30AM
09:39AM
09:22AM
07:45AM
05:52AM
Aug-11-22 04:02PM
06:15AM
Aug-10-22 03:16PM
01:15PM
05:21AM
Aug-09-22 04:15PM
04:05PM
04:00PM
03:59PM
03:06PM
01:41PM
12:58PM
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YOUNG JAMES FDirectorMar 31Sale73.5812,500919,76562,590Apr 04 05:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Option Exercise19.085,00095,4008,845Jan 05 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Sale140.915,000704,5343,845Jan 05 05:22 PM
YOUNG JAMES FDirectorDec 31Option Exercise25.603,75096,00078,840Jan 04 05:04 PM
YOUNG JAMES FDirectorDec 31Sale144.163,750540,60175,090Jan 04 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Option Exercise19.085,00095,4008,845Dec 22 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Sale230.005,0001,150,0003,845Dec 22 05:03 PM
Glenn Gregory MPresident, R&DDec 15Option Exercise34.821,68658,7147,349Dec 16 05:15 PM
Glenn Gregory MPresident, R&DDec 15Sale174.131,686293,5845,663Dec 16 05:15 PM
DOUGLAS RICHARDDirectorDec 13Option Exercise25.601,50038,40033,450Dec 15 05:22 PM
Glenn Gregory MPresident, R&DDec 07Option Exercise19.088,250157,41012,311Dec 09 05:20 PM
Glenn Gregory MPresident, R&DDec 07Sale170.148,2501,403,6314,061Dec 09 05:20 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Option Exercise19.085,00095,4007,760Dec 03 06:30 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Sale196.195,000980,9442,760Dec 03 06:30 PM
Glenn Gregory MPresident, R&DNov 30Option Exercise19.088,250157,41013,003Dec 02 04:13 PM
Glenn Gregory MPresident, R&DNov 30Sale203.208,9421,817,0004,061Dec 02 04:13 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 29Option Exercise19.085,00095,4007,760Dec 01 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 29Sale228.725,0001,143,6002,760Dec 01 05:02 PM
Glenn Gregory MPresident, R&DNov 26Option Exercise5.953,46020,5876,144Nov 30 05:06 PM
Glenn Gregory MPresident, R&DNov 26Sale218.072,083454,2474,061Nov 30 05:06 PM
Glenn Gregory MPresident, R&DNov 23Option Exercise19.088,250157,41012,311Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 23Sale199.508,2501,645,9144,061Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 16Option Exercise19.088,250157,41012,311Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 16Sale169.488,2501,398,1804,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Option Exercise37.901,18344,8325,244Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Sale172.021,183203,4964,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 09Option Exercise19.088,250157,41012,311Nov 12 05:02 PM
Glenn Gregory MPresident, R&DNov 09Sale167.538,2501,382,1604,061Nov 12 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Option Exercise19.085,00095,4007,760Nov 05 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Sale200.005,0001,000,0002,760Nov 05 05:02 PM
Glenn Gregory MPresident, R&DNov 02Option Exercise19.088,250157,41012,311Nov 04 05:22 PM
Glenn Gregory MPresident, R&DNov 02Sale183.828,2501,516,5524,061Nov 04 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Option Exercise19.085,00095,4007,760Nov 03 04:49 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Sale163.085,000815,4222,760Nov 03 04:49 PM
Glenn Gregory MPresident, R&DOct 29Sale148.34680100,8714,061Nov 02 07:02 PM
Glenn Gregory MPresident, R&DOct 26Option Exercise15.2011,712178,00914,395Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 26Sale132.7310,3341,371,6674,061Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 19Option Exercise19.088,250157,41012,311Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 19Sale165.148,2501,362,4274,061Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 15Option Exercise37.901,18344,8325,244Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 15Sale170.001,183201,1104,061Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 12Option Exercise19.088,250157,41012,311Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 12Sale163.188,2501,346,2184,061Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 05Option Exercise19.088,250157,41012,311Oct 07 05:18 PM
Glenn Gregory MPresident, R&DOct 05Sale174.418,2501,438,8954,061Oct 07 05:18 PM
Erck Stanley CPresident and CEOOct 04Option Exercise27.4542,8291,175,58366,708Oct 05 05:05 PM
Erck Stanley CPresident and CEOOct 04Sale176.1542,8297,544,19523,879Oct 05 05:05 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Option Exercise19.085,00095,4007,760Oct 05 05:02 PM
Erck Stanley CPresident and CEOOct 01Option Exercise27.1749,0001,331,40072,879Oct 05 05:04 PM
Erck Stanley CPresident and CEOOct 01Sale175.1049,0008,580,06423,879Oct 05 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Sale174.895,000874,4522,760Oct 05 05:02 PM
Glenn Gregory MPresident, R&DSep 30Sale207.25693143,6224,061Oct 01 05:58 PM
Trizzino JohnEVP, CCO and CBOSep 28Option Exercise19.087,501143,11910,047Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 28Sale209.927,5011,574,6372,546Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 27Option Exercise19.087,501143,11910,047Sep 29 05:04 PM
Glenn Gregory MPresident, R&DSep 27Option Exercise5.953,46020,5876,144Sep 29 05:08 PM
Glenn Gregory MPresident, R&DSep 27Sale234.432,083488,3154,061Sep 29 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 27Sale234.617,5011,759,8332,546Sep 29 05:04 PM